The one-eye trial and fellow eye response to prostaglandin analogues

Clinical and Experimental Ophthalmology

Volumn 36, Issue 2, 2008, Pages 136-141

  Dayanir, Volkan ^a   Cakmak, Harun ^a   Berkit, Ilker ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Ffellow eye; Intraocular pressure; Office hours; One eye trial; Prostaglandin analogues

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TRAVOPROST;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CASE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; EXFOLIATION SYNDROME; FEASIBILITY STUDY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; PREDICTION; PRESSURE MEASUREMENT; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS, SYNTHETIC; RETROSPECTIVE STUDIES; TIME FACTORS; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 41249092069     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2008.01698.x     Document Type: Article

References (21)

1. Collaborative Normal-tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-97.
2. Gordon MO, Beiser JA, Brandt JD et al. The Ocular Hypertension Treatment Study. Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-20; discussion 829-30.
3. Leske MC, Heijl A, Hussein M et al. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56.
4. Kass MA, Heuer DK, Higginbotham EJ et al., the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13.
5. Heijl A, Leske MC, Bengtsson B etal. Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
6. The AGIS, Investigators: The Advanced Glaucoma Intervention Study (AGIS) 7: The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
7. Realini T, Fechtner RD, Atreides SP, Gollance S. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology 2004; 111: 421-6.
8. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-42.
9. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: A retrospective review. J Glaucoma 2003; 12: 232-6.
10. David R, Zangwill L, Briscoe D, Dagan M, Yagev R, Yassur Y. Diurnal intraocular pressure variations: An analysis of 690 diurnal curves. Br J Ophthalmol 1992; 76: 280-3.
11. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol 2005; 139: 320-4.
12. Wilensky JT, Gieser DK, Mori MT, Langenberg PW, Zeimer RC. Self-tonometry to manage patients with glaucoma and apparently controlled intraocular pressure. Arch Ophthalmol 1987; 105: 1072-5.
13. American Academy of Ophthalmology Preferred Practice Pattern Collection. Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology, 2003.
14. Wilensky JT. The role of diurnal pressure measurements in the management of open angle glaucoma. Curr Opin Ophthalmol 2004; 15: 90-2.
15. Netland PA, Landry T, Sullivan EK etal. Travoprost compared with Latanoprost and Timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472-84.
16. Brandt JD, VanDenburgh AM, Chen K. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology 2001; 108: 1023-31.
17. Hedman K, Watson PG, Alm A. The effect of Latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002; 47 (Suppl. 1): S65-76.
18. Thorburn W. The accuracy of clinical applanation tonometry. Acta Ophthalmol (Copenh) 1978; 56: 1-5.
19. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of Latanoprost in humans. Surv Ophthalmol 2002; 47 (Suppl. 1): S6-12.
20. Piltz-Seymour J, Jampel H. The one-eye drug trial revisited. Ophthalmology 2004; 111: 419-20.
21. Realini T, Vickers WR. Symmetry of fellow-eye intraocular pressure responses to topical glaucoma medications. Ophthalmology 2005; 112: 599-602.